CMH “sells” patents to CMTH (which has the ticker CELZ). CMTH then generates “revenues” through the sale of what amounts to a syringe kit: early data from 2018 indicates that CMTH makes about $1,200 net per kit—and in nearly 3 years of “commercialization” of this sort, they are now offering CaverStem in a whopping 40 sites worldwide. This, mind you, is their “cash cow”...